BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berretta M, Rinaldi L, Di Benedetto F, Lleshi A, De Re V, Facchini G, De Paoli P, Di Francia R. Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Front Pharmacol 2016;7:428. [PMID: 27881963 DOI: 10.3389/fphar.2016.00428] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Tan LT, Chan KG, Pusparajah P, Lee WL, Chuah LH, Khan TM, Lee LH, Goh BH. Targeting Membrane Lipid a Potential Cancer Cure? Front Pharmacol 2017;8:12. [PMID: 28167913 DOI: 10.3389/fphar.2017.00012] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 7.4] [Reference Citation Analysis]
2 Pan L, Xiao H, Liao R, Chen Q, Peng C, Zhang Y, Mu T, Wu Z. Fatty acid binding protein 5 promotes tumor angiogenesis and activates the IL6/STAT3/VEGFA pathway in hepatocellular carcinoma. Biomed Pharmacother 2018;106:68-76. [PMID: 29957468 DOI: 10.1016/j.biopha.2018.06.040] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
3 Baby J, Devan AR, Kumar AR, Gorantla JN, Nair B, Aishwarya TS, Nath LR. Cogent role of flavonoids as key orchestrators of chemoprevention of hepatocellular carcinoma: A review. J Food Biochem 2021;45:e13761. [PMID: 34028054 DOI: 10.1111/jfbc.13761] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
4 Rimassa L, Danesi R, Pressiani T, Merle P. Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma. Cancer Treat Rev 2019;77:20-8. [PMID: 31195212 DOI: 10.1016/j.ctrv.2019.05.004] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 16.3] [Reference Citation Analysis]
5 Kim KM, Roh JH, Lee S, Yoon JH. Do renin-angiotensin system inhibitors reduce risk for hepatocellular carcinoma?: A nationwide nested case-control study. Clin Res Hepatol Gastroenterol 2021;45:101510. [PMID: 33272886 DOI: 10.1016/j.clinre.2020.07.015] [Reference Citation Analysis]
6 Matsuyama A, Takagi S, Hosoya K, Kagawa Y, Nakamura K, Deguchi T, Takiguchi M. Impact of surgical margins on survival of 37 dogs with massive hepatocellular carcinoma. N Z Vet J 2017;65:227-31. [PMID: 28441916 DOI: 10.1080/00480169.2017.1319304] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
7 Di Costanzo GG, Casadei Gardini A, Marisi G, Foschi FG, Scartozzi M, Granata R, Faloppi L, Cascinu S, Silvestris N, Brunetti O, Palmieri VO, Ercolani G, Tortora R. Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. Targ Oncol 2017;12:795-803. [DOI: 10.1007/s11523-017-0522-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
8 Ovais M, Ahmad I, Khalil AT, Mukherjee S, Javed R, Ayaz M, Raza A, Shinwari ZK. Wound healing applications of biogenic colloidal silver and gold nanoparticles: recent trends and future prospects. Appl Microbiol Biotechnol 2018;102:4305-18. [DOI: 10.1007/s00253-018-8939-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 12.3] [Reference Citation Analysis]
9 Refolo MG, D'Alessandro R, Lippolis C, Carella N, Cavallini A, Messa C, Carr BI. IGF-1R tyrosine kinase inhibitors and Vitamin K1 enhance the antitumor effects of Regorafenib in HCC cell lines. Oncotarget 2017;8:103465-76. [PMID: 29262576 DOI: 10.18632/oncotarget.21403] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
10 Morshedi K, Borran S, Ebrahimi MS, Masoud Khooy MJ, Seyedi ZS, Amiri A, Abbasi-Kolli M, Fallah M, Khan H, Sahebkar A, Mirzaei H. Therapeutic effect of curcumin in gastrointestinal cancers: A comprehensive review. Phytother Res 2021. [PMID: 34173992 DOI: 10.1002/ptr.7119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Yüksel Ş, Boylu Akyerli C, Cengiz Yakıcıer M. Angiogenesis, Invasion, and Metastasis Characteristics of Hepatocellular Carcinoma. J Gastrointest Cancer 2017;48:256-9. [PMID: 28785955 DOI: 10.1007/s12029-017-9962-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
13 Taskaeva I, Bgatova N. Microvasculature in hepatocellular carcinoma: An ultrastructural study. Microvasc Res 2021;133:104094. [PMID: 33011171 DOI: 10.1016/j.mvr.2020.104094] [Reference Citation Analysis]
14 Crisci S, Amitrano F, Saggese M, Muto T, Sarno S, Mele S, Vitale P, Ronga G, Berretta M, Di Francia R. Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology. Medicina (Kaunas) 2019;55:E414. [PMID: 31357735 DOI: 10.3390/medicina55080414] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Li Q, Xiong DL, Wang H, Jin WL, Ma YY, Fan XM. High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma. Onco Targets Ther 2021;14:2975-88. [PMID: 33981147 DOI: 10.2147/OTT.S296187] [Reference Citation Analysis]
16 Sun DS, Guan CH, Wang WN, Hu ZT, Zhao YQ, Jiang XM. LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211-5p/FOXD1/VEGF-A axis. Microvasc Res 2021;134:104120. [PMID: 33309645 DOI: 10.1016/j.mvr.2020.104120] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Abdel-Mohsen HT, Abdullaziz MA, Kerdawy AME, Ragab FAF, Flanagan KJ, Mahmoud AEE, Ali MM, Diwani HIE, Senge MO. Targeting Receptor Tyrosine Kinase VEGFR-2 in Hepatocellular Cancer: Rational Design, Synthesis and Biological Evaluation of 1,2-Disubstituted Benzimidazoles. Molecules 2020;25:E770. [PMID: 32053964 DOI: 10.3390/molecules25040770] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
18 Peña-Asensio J, Calvo H, Torralba M, Miquel J, Sanz-de-Villalobos E, Larrubia JR. Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1922. [PMID: 33923463 DOI: 10.3390/cancers13081922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Barone M, Viggiani MT, Losurdo G, Principi M, Leo AD. Systematic review: Renin-angiotensin system inhibitors in chemoprevention of hepatocellular carcinoma. World J Gastroenterol 2019; 25(20): 2524-2538 [PMID: 31171895 DOI: 10.3748/wjg.v25.i20.2524] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
20 Wang W, Zhang M, Peng Y, He J. Ubiquitin Associated Protein 2-Like (UBAP2L) Overexpression in Patients with Hepatocellular Carcinoma and its Clinical Significance. Med Sci Monit 2017;23:4779-88. [PMID: 28981479 DOI: 10.12659/msm.907071] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
21 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
22 Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res 2017;8:591-605. [PMID: 28808589 DOI: 10.1016/j.jare.2017.06.006] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 16.2] [Reference Citation Analysis]
23 Di Francia R, Berretta M, Benincasa G, D'Avino A, Facchini S, Costagliola D, Rossi P. Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors. Cells 2019;8:E522. [PMID: 31151284 DOI: 10.3390/cells8060522] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
24 Meleddu R, Deplano S, Maccioni E, Ortuso F, Cottiglia F, Secci D, Onali A, Sanna E, Angeli A, Angius R, Alcaro S, Supuran CT, Distinto S. Selective inhibition of carbonic anhydrase IX and XII by coumarin and psoralen derivatives. J Enzyme Inhib Med Chem 2021;36:685-92. [PMID: 33602041 DOI: 10.1080/14756366.2021.1887171] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Wang Y, Zhang S, Liu J, Fang B, Yao J, Cheng B. Matrine inhibits the invasive and migratory properties of human hepatocellular carcinoma by regulating epithelial‑mesenchymal transition. Mol Med Rep 2018;18:911-9. [PMID: 29845189 DOI: 10.3892/mmr.2018.9023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
26 Bousseau S, Vergori L, Soleti R, Lenaers G, Martinez MC, Andriantsitohaina R. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis. Pharmacology & Therapeutics 2018;191:92-122. [DOI: 10.1016/j.pharmthera.2018.06.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
27 Roy G, Guan S, Liu H, Zhang L. Rotundic Acid Induces DNA Damage and Cell Death in Hepatocellular Carcinoma Through AKT/mTOR and MAPK Pathways. Front Oncol 2019;9:545. [PMID: 31293977 DOI: 10.3389/fonc.2019.00545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Shaik F, Cuthbert GA, Homer-Vanniasinkam S, Muench SP, Ponnambalam S, Harrison MA. Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy. Biomolecules 2020;10:E1673. [PMID: 33333800 DOI: 10.3390/biom10121673] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
29 Xie JY, Wei JX, Lv LH, Han QF, Yang WB, Li GL, Wang PX, Wu SB, Duan JX, Zhuo WF, Liu PQ, Min J. Angiopoietin-2 induces angiogenesis via exosomes in human hepatocellular carcinoma. Cell Commun Signal 2020;18:46. [PMID: 32183816 DOI: 10.1186/s12964-020-00535-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
30 Vatnikov Y, Vilkovysky I, Kulikov E, Popova I, Khairova N, Gazin A, Zharov A, Lukina D. Size of canine hepatocellular carcinoma as an adverse prognostic factor for surgery. J Adv Vet Anim Res 2020;7:127-32. [PMID: 32219118 DOI: 10.5455/javar.2020.g401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Wang KF, Chen YD, Mo LQ, Zhang Z, Liu YJ, Chen JX, Sui XB, Xie T, Wu SX. Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment. Shijie Huaren Xiaohua Zazhi 2019; 27(7): 459-466 [DOI: 10.11569/wcjd.v27.i7.459] [Reference Citation Analysis]
32 Li X, Diao W, Xue H, Wu F, Wang W, Jiang B, Bai J, Lian B, Feng W, Sun T, Yu W, Wu J, Qu M, Wang Y, Gao Z. Improved efficacy of doxorubicin delivery by a novel dual-ligand-modified liposome in hepatocellular carcinoma. Cancer Lett 2020;489:163-73. [PMID: 32592729 DOI: 10.1016/j.canlet.2020.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
33 Fan Z, Zheng W, Li H, Wu W, Liu X, Sun Z, Hu H, Du L, Jia Q, Liu Q. LOXL2 upregulates hypoxia‑inducible factor‑1α signaling through Snail‑FBP1 axis in hepatocellular carcinoma cells. Oncol Rep 2020;43:1641-9. [PMID: 32323822 DOI: 10.3892/or.2020.7541] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Guo W, Li H, Liu H, Ma X, Yang S, Wang Z. DEPDC1 drives hepatocellular carcinoma cell proliferation, invasion and angiogenesis by regulating the CCL20/CCR6 signaling pathway. Oncol Rep 2019;42:1075-89. [PMID: 31322256 DOI: 10.3892/or.2019.7221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
35 Barbhuiya MA, Mirando AC, Simons BW, Lemtiri-Chlieh G, Green JJ, Popel AS, Pandey NB, Tran PT. Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma. Oncotarget 2017;8:101520-34. [PMID: 29254183 DOI: 10.18632/oncotarget.21148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Galal El-Shemi A, Mohammed Ashshi A, Oh E, Jung BK, Basalamah M, Alsaegh A, Yun CO. Efficacy of combining ING4 and TRAIL genes in cancer-targeting gene virotherapy strategy: first evidence in preclinical hepatocellular carcinoma. Gene Ther 2018;25:54-65. [PMID: 28925992 DOI: 10.1038/gt.2017.86] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
37 Pan Z, Zhuang J, Ji C, Cai Z, Liao W, Huang Z. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett 2018;15:4821-6. [PMID: 29552121 DOI: 10.3892/ol.2018.7988] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]